AU2013295014B2 - Vaccine compositions - Google Patents

Vaccine compositions Download PDF

Info

Publication number
AU2013295014B2
AU2013295014B2 AU2013295014A AU2013295014A AU2013295014B2 AU 2013295014 B2 AU2013295014 B2 AU 2013295014B2 AU 2013295014 A AU2013295014 A AU 2013295014A AU 2013295014 A AU2013295014 A AU 2013295014A AU 2013295014 B2 AU2013295014 B2 AU 2013295014B2
Authority
AU
Australia
Prior art keywords
gly
thr
leu
val
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013295014A
Other languages
English (en)
Other versions
AU2013295014A1 (en
Inventor
Alain Bouckenooghe
Remi Forrat
Jean Lang
Melanie Saville
Nadia TORNIEPORTH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Inc
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of AU2013295014A1 publication Critical patent/AU2013295014A1/en
Application granted granted Critical
Publication of AU2013295014B2 publication Critical patent/AU2013295014B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2013295014A 2012-07-24 2013-07-24 Vaccine compositions Active AU2013295014B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12305907.3 2012-07-24
EP12305907 2012-07-24
EP12305912 2012-07-25
EP12305912.3 2012-07-25
PCT/EP2013/065667 WO2014016360A1 (en) 2012-07-24 2013-07-24 Vaccine compositions

Publications (2)

Publication Number Publication Date
AU2013295014A1 AU2013295014A1 (en) 2015-01-29
AU2013295014B2 true AU2013295014B2 (en) 2018-01-18

Family

ID=48875047

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013295014A Active AU2013295014B2 (en) 2012-07-24 2013-07-24 Vaccine compositions

Country Status (12)

Country Link
US (2) US20150196631A1 (enExample)
EP (2) EP3932422A1 (enExample)
JP (2) JP2015524421A (enExample)
KR (2) KR20200067938A (enExample)
CN (1) CN104812407B (enExample)
AU (1) AU2013295014B2 (enExample)
CA (1) CA2878682A1 (enExample)
MX (2) MX381497B (enExample)
MY (2) MY168959A (enExample)
PH (1) PH12014502840B1 (enExample)
SG (2) SG11201500412TA (enExample)
WO (1) WO2014016360A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014016362A1 (en) * 2012-07-24 2014-01-30 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
KR102389908B1 (ko) 2013-03-15 2022-04-26 다케다 백신즈 인코포레이티드 백신 내의 뎅기 바이러스 키메라 구조체를 위한 조성물 및 방법
TWI852899B (zh) * 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
CN107405392B (zh) * 2015-02-09 2021-05-18 中央研究院 用于增强对抗登革病毒的安全性及免疫力的抗原表位替换的疫苗
EP3316905A1 (en) * 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
EP3147294B1 (en) * 2015-09-24 2020-04-29 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Distinguishing dengue virus infections from other flaviviral infections using a recombinant mutant envelope protein
MY194650A (en) * 2015-11-27 2022-12-09 Km Biologics Co Ltd Multivalent dengue vaccine composition comprising a mixture of attenuated dengue viruses from different serotypes
KR102611235B1 (ko) * 2016-04-13 2023-12-08 다케다 백신즈 인코포레이티드 어린이 및 젊은 성인에서 뎅기 바이러스에 대한 백신접종 조성물 및 방법
US11531029B2 (en) 2017-05-08 2022-12-20 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods and compositions for the detection of flavivirus infections
JP7313345B2 (ja) * 2017-10-05 2023-07-24 サノフィ・パスツール デング熱に対するブースターワクチン接種のための組成物
WO2019113285A2 (en) 2017-12-06 2019-06-13 Emory University Zika vaccines and methods of use
EP3549603A1 (en) 2018-04-06 2019-10-09 Sanofi Pasteur Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
ES2908304T3 (es) 2018-09-05 2022-04-28 Takeda Vaccines Inc Dosis unitaria de vacuna contra el dengue y administración de la misma
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
CN112079934B (zh) * 2019-12-17 2021-01-29 合源生物科技(天津)有限公司 一种靶向cd19的嵌合抗原受体及其用途
CN116334070A (zh) * 2023-02-15 2023-06-27 天津大学 融合蛋白的应用和细胞融合的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040259224A1 (en) * 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
WO2008047023A2 (fr) * 2006-10-04 2008-04-24 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422A (en) 1848-02-01 Spark-arrester
US109A (en) 1836-12-15 Erawijtg
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6254873B1 (en) 1995-04-17 2001-07-03 The United States Of America As Represented By The Secretary Of The Army Inactivated dengue virus vaccine
WO1996040933A1 (en) 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine
ES2244050T3 (es) 1997-02-28 2005-12-01 Acambis Inc. Vacunas quimericas de flavivirus.
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
DE69838992T2 (de) 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Öl-in-Wasser Emulsionen mit Saponinen
AU4040400A (en) 1999-03-26 2000-10-16 Walter Reed Army Institute Of Research Attenuated dengue-4 virus vaccine
US6528065B1 (en) 1999-03-26 2003-03-04 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-3 virus vaccine
JP2002540169A (ja) 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 弱毒化デング熱１型ウイルスワクチン
US6511667B1 (en) 1999-03-26 2003-01-28 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-2 virus vaccine
WO2001060847A2 (en) 2000-02-16 2001-08-23 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Avirulent, immunogenic flavivirus chimeras
ATE412738T1 (de) 2000-05-30 2008-11-15 Univ Mahidol Attenuierte stammen von denguevirus und ihre verwendungen in impfstoffzusammensetzungen
AT410634B (de) 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
CA2966716C (en) 2001-05-22 2019-11-26 The Government Of The United States Of America, As Represented By The Cretary, Department Of Health And Human Services Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
WO2002095007A2 (en) 2001-05-23 2002-11-28 Dendreon San Diego Llc Conjugates activated by cell surface proteases and therapeutic uses thereof
US7569383B2 (en) 2001-06-01 2009-08-04 Acambis Inc. Chimeric flavivirus vectors
EP2295023A1 (en) * 2002-01-15 2011-03-16 Sanofi Pasteur Biologics Co. Flavivirus vaccines
CA2611934C (en) 2005-06-17 2015-11-03 Sanofi Pasteur Dengue serotype 1 attenuated strain
MX2007015872A (es) 2005-06-17 2008-04-21 Sanofi Pasteur Cepa atenuada del serotipo 2 del dengue.
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
EP1924280A4 (en) 2005-08-10 2008-12-10 Acambis Inc VACCINATION AGAINST DENGUE VIRUS INFECTION
AU2006315026B2 (en) * 2005-11-21 2012-11-22 Sanofi Pasteur Limited Stabilizing formulations for recombinant viruses
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2909286B1 (fr) 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
GB201007531D0 (en) 2010-05-05 2010-06-23 Imp Innovations Ltd Composition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040259224A1 (en) * 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
WO2008047023A2 (fr) * 2006-10-04 2008-04-24 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BHAMARAPRAVATI N ET AL, "Live attenuated tetravalent dengue vaccine", VACCINE, ELSEVIER LTD, GB, (20000101), vol. 18, doi:10.1016/S0264-410X(00)00040-2, ISSN 0264-410X, pages 44 - 47 *
Bruno Guy, "Development of Sanofi Pasteur tetravalent dengue vaccine", vol. 6, no. 9, doi:DOI: 10.4161.hv.6.9.12739, (20100901), pages 696 - 705, URL: http://www.orphanresearch.com/journals/vaccines/GuyHV6-9.pdf, (20121203) *
JORGE E OSORIO ET AL, "Development of DENVax: A chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever", VACCINE, vol. 29, no. 42, doi:10.1016/J.VACCINE.2011.07.020, (2011), pages 7251 - 7260, (20110711) *
SHUO ZHANG ET AL, "Vaccination with dengue virus-like particles induces humoral and cellular immune responses in mice", VIROLOGY JOURNAL, BIOMED CENTRAL, LONDON, GB, (20110630), vol. 8, no. 1, doi:10.1186/1743-422X-8-333, page 333 *

Also Published As

Publication number Publication date
MX2021004211A (es) 2021-05-27
AU2013295014A1 (en) 2015-01-29
MX381497B (es) 2025-03-12
EP3932422A1 (en) 2022-01-05
MY168959A (en) 2019-01-28
KR20200067938A (ko) 2020-06-12
JP6830118B2 (ja) 2021-02-17
PH12014502840A1 (en) 2015-02-23
WO2014016360A1 (en) 2014-01-30
MX2015000442A (es) 2015-03-12
HK1212906A1 (zh) 2016-06-24
KR20150036592A (ko) 2015-04-07
SG10201912291YA (en) 2020-02-27
CN104812407B (zh) 2022-11-22
CA2878682A1 (en) 2014-01-30
CN104812407A (zh) 2015-07-29
US20190201517A1 (en) 2019-07-04
US20150196631A1 (en) 2015-07-16
SG11201500412TA (en) 2015-02-27
JP2015524421A (ja) 2015-08-24
EP2877208A1 (en) 2015-06-03
JP2019151636A (ja) 2019-09-12
EP2877208B1 (en) 2021-05-12
PH12014502840B1 (en) 2015-02-23
MY197723A (en) 2023-07-10

Similar Documents

Publication Publication Date Title
AU2013295014B2 (en) Vaccine compositions
US20150265695A1 (en) Vaccine compositions for prevention against dengue virus infection
JP5227172B2 (ja) デングウイルス感染に対するワクチン接種
US10946087B2 (en) Vaccine compositions against dengue virus diseases
EP3010536A1 (en) Dengue virus vaccine compositions and methods of use thereof
WO2014083194A1 (en) Methods for inducing antibodies
WO2019069130A1 (en) COMPOSITIONS FOR RECALL VACCINATION AGAINST DENGUE
HK1212906B (en) Vaccine compositions
BR112015001145B1 (pt) Composição de vacina para uso em um método de proteção de um indivíduo humano contra a doença da dengue, kit compreendendo a mesma e seu uso
HK1242193A1 (en) Vaccine compositions against dengue virus diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)